Back to Journals » Cancer Management and Research » Volume 6

Future of bisphosphonates and denosumab for men with advanced prostate cancer

Authors Iranikhah M, Stricker S, Freeman MK

Received 11 November 2013

Accepted for publication 20 January 2014

Published 3 May 2014 Volume 2014:6 Pages 217—224


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Maryam Iranikhah, Steve Stricker, Maisha Kelly Freeman

Samford University, McWhorter School of Pharmacy, Birmingham, AL, USA

Abstract: Prostate cancer is the most common cancer occurring in American men of all races. It is also the second leading cause of cancer death among men in the USA. Bone metastasis is a frequent occurrence in men with advanced prostate cancer, with skeletal-related events being a common complication and having negative consequences, leading to severe pain, increased health care costs, increased risk of death, and decreased quality of life for patients. Bone loss can also result from antiandrogen therapy, which can further contribute to skeletal-related events. Treatment with antiresorptive agents bisphosphonates, and the newly approved denosumab, a receptor activator of nuclear factor kappa-B ligand (RANK-L) inhibitor, has been shown to reduce the risk of skeletal-related complications and prevent treatment-induced bone loss in patients with advanced prostate cancer. This review discusses the role of antiresorptive agents bisphosphonates and RANK-L inhibitor in the current treatment of advanced prostate cancer by examining the primary literature and also focuses on the likely role of the bisphosphonates in the treatment of advanced prostate cancer in the future.

Keywords: prostate cancer, bisphosphonates, skeletal-related events, RANK-L inhibitor, malignancy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]